ATE382680T1 - Nährmedium für cho-zellen und daran angepasste zellen - Google Patents

Nährmedium für cho-zellen und daran angepasste zellen

Info

Publication number
ATE382680T1
ATE382680T1 AT02003143T AT02003143T ATE382680T1 AT E382680 T1 ATE382680 T1 AT E382680T1 AT 02003143 T AT02003143 T AT 02003143T AT 02003143 T AT02003143 T AT 02003143T AT E382680 T1 ATE382680 T1 AT E382680T1
Authority
AT
Austria
Prior art keywords
cells
cho
culture medium
adaptable
source
Prior art date
Application number
AT02003143T
Other languages
English (en)
Inventor
Michael John Keen
Nicholas Timothy Rapson
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10683864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE382680(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of ATE382680T1 publication Critical patent/ATE382680T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0043—Medium free of human- or animal-derived components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/74—Undefined extracts from fungi, e.g. yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/76—Undefined extracts from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/395—Thyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Materials For Medical Uses (AREA)
  • Liquid Crystal (AREA)
AT02003143T 1990-10-17 1991-10-17 Nährmedium für cho-zellen und daran angepasste zellen ATE382680T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9022545A GB9022545D0 (en) 1990-10-17 1990-10-17 Culture medium

Publications (1)

Publication Number Publication Date
ATE382680T1 true ATE382680T1 (de) 2008-01-15

Family

ID=10683864

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02003143T ATE382680T1 (de) 1990-10-17 1991-10-17 Nährmedium für cho-zellen und daran angepasste zellen
AT91309596T ATE248217T1 (de) 1990-10-17 1991-10-17 Nährmedium für cho-zellen und daran angepasste zellen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT91309596T ATE248217T1 (de) 1990-10-17 1991-10-17 Nährmedium für cho-zellen und daran angepasste zellen

Country Status (13)

Country Link
US (4) US5316938A (de)
EP (3) EP1849862A3 (de)
JP (1) JP2625302B2 (de)
AT (2) ATE382680T1 (de)
AU (1) AU645615B2 (de)
CA (1) CA2053586C (de)
DE (2) DE69133303T2 (de)
DK (2) DK0481791T3 (de)
ES (2) ES2298301T3 (de)
GB (1) GB9022545D0 (de)
IE (1) IE913559A1 (de)
NZ (1) NZ240248A (de)
ZA (1) ZA918249B (de)

Families Citing this family (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292655A (en) * 1990-01-29 1994-03-08 Wille Jr John J Method for the formation of a histologically-complete skin substitute
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
JPH0789908B2 (ja) * 1991-02-28 1995-10-04 倉敷紡績株式会社 動物細胞培養用無血清培地
DE4115722A1 (de) * 1991-05-14 1992-11-19 Boehringer Mannheim Gmbh Serumfreies medium zur kultivierung von saeugerzellen
GB9118664D0 (en) * 1991-08-30 1991-10-16 Celltech Ltd Cell culture
US6231881B1 (en) 1992-02-24 2001-05-15 Anton-Lewis Usala Medium and matrix for long-term proliferation of cells
US6352707B1 (en) 1992-02-24 2002-03-05 Anton-Lewis Usala Transplant encapsulation in a hydrogel matrix to obscure immune recognition
IL102929A (en) * 1992-08-24 1996-11-14 Interpharm Lab Ltd Serum-free medium for mammalian cells
DE4313620A1 (de) * 1993-04-26 1994-10-27 Biotechnolog Forschung Gmbh Hamsterzellinien und Verfahren zur Glykoproteingewinnung
USH1532H (en) * 1993-11-03 1996-05-07 Genetics Institute, Inc. Adaption of mammalian cell lines to high cell densities
EP0653487A1 (de) * 1993-11-07 1995-05-17 Ferruccio Dr. Messi Serum- und proteinfrei wachsende Zellen
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5512477A (en) * 1994-04-21 1996-04-30 Genzyme Corporation Serum-free medium supplement
US5753489A (en) * 1994-11-10 1998-05-19 Immuno Ag Method for producing viruses and vaccines in serum-free culture
US5698433A (en) * 1994-11-10 1997-12-16 Immuno Ag Method for producing influenza virus and vaccine
US5756341A (en) * 1994-11-10 1998-05-26 Immuno Ag Method for controlling the infectivity of viruses
US6146873A (en) * 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US6656466B1 (en) * 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
JP2000507812A (ja) * 1996-03-12 2000-06-27 ライフ テクノロジーズ，インコーポレイテッド 造血細胞培養栄養補充成分
WO1997038090A1 (en) * 1996-04-09 1997-10-16 Board Of The Trustees Of Southern Illinois University A cultural medium for maintaining neural cells in ambient atmosphere
EP2221361A3 (de) * 1996-08-30 2011-02-09 Life Technologies Corporation Methode zur Herstellung eines Polypeptids in vitro in einer Säugerzelle in einem Kulturmedium ohne Serum und ohne Proteine
DE69738806D1 (de) * 1996-10-10 2008-08-14 Invitrogen Corp Tierzellkulturmedium mit pflanzlichen nährstoffen
US20040171152A1 (en) * 1996-10-10 2004-09-02 Invitrogen Corporation Animal cell culture media comprising non-animal or plant-derived nutrients
US6692961B1 (en) * 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
US20020012991A1 (en) * 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6566118B1 (en) * 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
WO1999057246A1 (en) * 1998-05-01 1999-11-11 Life Technologies, Inc. Animal cell culture media comprising non-animal or plant-derived nutrients
US6528286B1 (en) * 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6406909B1 (en) * 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
US7294481B1 (en) * 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
PT1914244E (pt) 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
US20060286668A1 (en) * 1999-04-30 2006-12-21 Invitrogen Corporation Animal-cell culture media comprising non-animal or plant-derived nutrients
AT409379B (de) * 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
EP1200561B1 (de) * 1999-08-05 2006-06-14 Baxter Aktiengesellschaft Rekombinanter stabiler zellklon, seine herstellung und verwendung
JP4668498B2 (ja) 1999-10-19 2011-04-13 協和発酵キリン株式会社 ポリペプチドの製造方法
KR20010056451A (ko) * 1999-12-15 2001-07-04 윤재승 아르기닌이 강화된 동물세포 배양용 배지 조성물
US6811776B2 (en) 2000-12-27 2004-11-02 The Regents Of The University Of Michigan Process for ex vivo formation of mammalian bone and uses thereof
JP2004520809A (ja) * 2000-08-23 2004-07-15 ファイザー・プロダクツ・インク 好中球阻害性因子を調製するためのプロセス
US20020099183A1 (en) * 2000-08-23 2002-07-25 Pluschkell Stefanie Beate Process for the preparation of neutrophil inhibitory factor
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
MXPA03005406A (es) 2000-12-20 2003-09-25 Hoffmann La Roche Conjugados de eritropoyetina.
US6506576B2 (en) 2001-03-14 2003-01-14 Board Of Trustees Of The University Of Arkansas Serum-and steroid-free culture media for cerebellar granule neurons
WO2003045995A2 (en) * 2001-11-28 2003-06-05 Sandoz Gmbh Cell culture process
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US8093357B2 (en) * 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US20080254027A1 (en) * 2002-03-01 2008-10-16 Bernett Matthew J Optimized CD5 antibodies and methods of using the same
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament
DK2287288T3 (da) 2002-07-09 2013-01-07 Baxter Int Medium frit for animalsk protein til dyrkning af celler
US7067279B1 (en) 2002-08-23 2006-06-27 Immunex Corporation Cell culture performance with betaine
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
AU2003274011B2 (en) 2002-10-15 2010-03-04 Intercell Ag Nucleic acids coding for adhesion factor of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
DE10255508A1 (de) * 2002-11-27 2004-06-17 Forschungszentrum Jülich GmbH Verfahren zur Kultivierung von Zellen zur Produktion von Substanzen
ES2354610T5 (es) † 2002-12-23 2020-09-14 Bristol Myers Squibb Co Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína
US20070275460A1 (en) * 2003-03-03 2007-11-29 Xencor.Inc. Fc Variants With Optimized Fc Receptor Binding Properties
GB0304799D0 (en) 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
EP1622941A2 (de) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Methode zur produktion von anti-egfr antikörpern
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
GB2404665B (en) * 2003-08-08 2005-07-06 Cambridge Antibody Tech Cell culture
PT1651754E (pt) * 2003-08-08 2007-07-06 Cambridge Antibody Tech Cultura de células de mieloma em meio de baixo teor de ferro e isento de transferrina.
KR20060076781A (ko) * 2003-09-18 2006-07-04 레이븐 바이오테크놀로지스, 인코퍼레이티드 세포 배양 배지
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US20070128691A1 (en) * 2003-10-09 2007-06-07 Ryosuke Nakano Genomically modified cell neutralized to serum-free system
WO2005033135A1 (en) * 2003-10-09 2005-04-14 Daewoong Co., Ltd. Process for purifying human thrombopoietin with high content of sialic acid
BRPI0415887B1 (pt) * 2003-10-27 2021-01-26 Wyeth métodos para a remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatita
EP1697520A2 (de) * 2003-12-22 2006-09-06 Xencor, Inc. Fc-polypeptide mit neuen fc-ligandenbindungsstellen
US7255288B2 (en) * 2004-03-08 2007-08-14 Wan Shan Chan Aroma therapy for fountain
EP1737890A2 (de) * 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulinvarianten ausserhalb der fc-region
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US20060074225A1 (en) * 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
AU2011221414B2 (en) * 2004-10-29 2012-09-20 Takeda Pharmaceutical Company Limited Animal Protein-Free Media for Cultivation of Cells
US20060094104A1 (en) * 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
NZ554131A (en) * 2004-11-02 2009-08-28 Ares Trading Sa Serum-free cell culture medium for mammalian cells
US8273553B2 (en) * 2004-11-02 2012-09-25 Ares Trading S.A. Production of growth hormone in serum-free cell culture medium for mammalian cells
SI1807504T1 (sl) * 2004-11-02 2011-05-31 Ares Trading Sa Brezserumski celiäśni kultivacijski medij za celice sesalcev
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
DK1817340T3 (da) 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
CA2595169A1 (en) * 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
WO2006084826A1 (en) * 2005-02-11 2006-08-17 Novo Nordisk Health Care Ag Production of a polypeptide in a serum-free cell culture liquid containing plant protein hydrolysate
JP2006310392A (ja) * 2005-04-26 2006-11-09 Toshiba Corp 電子ビーム描画方法及び電子ビーム描画装置
JP2008541746A (ja) * 2005-06-03 2008-11-27 ビオヴィトルム・アクチボラゲット（プブリクト） 新規プロセス
TWI369401B (en) 2005-07-05 2012-08-01 Ares Trading Sa Serum-free culture medium for the production of recombinant gonadotropins
EP1931709B1 (de) * 2005-10-03 2016-12-07 Xencor, Inc. Fc-varianten mit optimierten rezeptorbindungseigenschaften
AU2006302254B2 (en) 2005-10-06 2011-05-26 Xencor, Inc. Optimized anti-CD30 antibodies
LT1974014T (lt) 2006-01-04 2017-11-27 Baxalta Incorporated Ląstelių kultūros terpė be oligopeptidų
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
CN101541950A (zh) 2006-07-13 2009-09-23 惠氏公司 糖蛋白的产生
DK2054074T3 (da) 2006-08-04 2014-11-03 Prolong Pharmaceuticals Llc Modificeret erythropoietin
SI2059536T1 (sl) 2006-08-14 2014-06-30 Xencor, Inc. Optimirana protitelesa, ki ciljajo CD19
EP2500415A1 (de) * 2006-09-13 2012-09-19 Abbott Laboratories Verbesserungen an Zellkulturen
AU2007294731B2 (en) * 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
AU2007299843B2 (en) * 2006-09-18 2012-03-08 Xencor, Inc Optimized antibodies that target HM1.24
JP5175336B2 (ja) 2007-04-16 2013-04-03 モメンタ ファーマシューティカルズ インコーポレイテッド 細胞表面グリコシル化に関連する方法
US20100279306A1 (en) * 2007-04-16 2010-11-04 Momenta Pharmaceuticals, Inc. Analysis of phosphorylated glycans, glycopeptides or glycoproteins by imac
EP2135089B1 (de) 2007-04-16 2015-09-02 Momenta Pharmaceuticals, Inc. Vergleichende analyse von protein konformationen unter verwendung von 2d noesy nmr spektren
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
WO2008136398A1 (ja) * 2007-04-26 2008-11-13 Chugai Seiyaku Kabushiki Kaisha 高濃度アミノ酸含有培地を用いた細胞の培養方法
GB0710614D0 (en) * 2007-06-04 2007-07-11 Lonza Biologics Plc Mammalian expression vector with a highly efficient secretory signal sequence
CN101319200B (zh) * 2007-06-08 2010-05-19 中国科学院大连化学物理研究所 一种适用于微囊化cho细胞的无血清培养基及其应用
WO2008154014A2 (en) * 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
US7580304B2 (en) * 2007-06-15 2009-08-25 United Memories, Inc. Multiple bus charge sharing
EP3327132A3 (de) * 2007-08-09 2018-07-18 Wyeth LLC Verwendung von perfusion zur erhöhung der produktion von fed-batch-zellkulturen in bioreaktoren
AU2008309934B2 (en) * 2007-10-12 2014-03-06 F. Hoffmann-La Roche Ag Protein expression from multiple nucleic acids
ES2532461T3 (es) 2007-12-26 2015-03-27 Xencor, Inc. Variantes de FC con enlazamiento alterado a FCRN
PT2235197T (pt) * 2007-12-27 2017-10-11 Baxalta Inc Processos para cultura de células
WO2009087087A1 (en) * 2008-01-09 2009-07-16 Cellca Gmbh Improved culture media additive and process for using it
JP2011512877A (ja) * 2008-03-12 2011-04-28 ワイス・エルエルシー 組換えタンパク質の大スケール産生に適した細胞を同定する方法
BRPI0822597A2 (pt) * 2008-04-18 2019-09-24 Shanghai Cp Guojian Pharmaceutical Co Ltd meio concetrado e sua utilização
DE102008002210A1 (de) 2008-06-04 2009-12-10 Evonik Degussa Gmbh Verfahren zur fermentativen Herstellung von Erythropoietin
ES2699434T3 (es) * 2008-10-31 2019-02-11 Wyeth Llc Purificación de proteínas ácidas utilizando cromatografía de hidroxiapatita cerámica
EP2356247B2 (de) * 2008-11-12 2019-05-15 Baxalta Incorporated Verfahren zur herstellung von serumfreiem insulinfreiem faktor vii
US20110250644A1 (en) * 2008-12-19 2011-10-13 Schering Corporation Feed supplement for mammalian cell culture and methods of use
AU2009327435A1 (en) 2008-12-19 2010-06-24 Momenta Pharmaceuticals, Inc. Methods related to modified glycans
AU2009334512B2 (en) 2008-12-30 2014-04-24 Takeda Pharmaceutical Company Limited Method of enhancing cell growth using alkyl-amine-n-oxide (AANOx)
PL2401383T3 (pl) * 2009-02-27 2014-02-28 Novartis Ag Sposoby selekcji komórek eukariotycznych wykazujących ekspresję heterologicznego białka
US8597943B2 (en) 2009-04-09 2013-12-03 Cellca Gmbh Method for improved single cell cloning
PL2451299T3 (pl) 2009-07-10 2016-09-30 Sposoby i kompozycje do leczenia schorzeń związanych z tarczycą z użyciem zredukowanych folianów
KR101573972B1 (ko) 2009-07-31 2015-12-02 백스터 인터내셔널 인코포레이티드 Ａｄａｍｔｓ 단백질 발현을 위한 세포 배양 배지
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US20120264688A1 (en) 2009-09-23 2012-10-18 Walter Hinderer Process for the purification of recombinant human erythropoietin (epo), epo thus purified and pharmaceutical compositions comprising same
BR112012009828B8 (pt) 2009-10-26 2022-10-25 Hoffmann La Roche Método para a produção de uma imunoglobulina glicosilada e seu uso
WO2011079004A1 (en) * 2009-12-23 2011-06-30 Schering Corporation Cell line 3m
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
PL3330370T3 (pl) 2010-04-26 2021-09-20 Novartis Ag Sposób hodowania komórek cho
SG185038A1 (en) 2010-04-26 2012-11-29 Novartis Ag Improved cell culture medium
CN102234627B (zh) * 2010-04-30 2015-06-03 中国科学院广州生物医药与健康研究院 一种培养基添加剂及其应用
CN103097409A (zh) 2010-07-08 2013-05-08 巴克斯特国际公司 在细胞培养物中生产重组高分子量vWF的方法
SG187198A1 (en) 2010-08-05 2013-03-28 Amgen Inc Dipeptides to enhance yield and viability from cell cultures
ES2710543T3 (es) 2010-12-27 2019-04-25 Kyowa Hakko Kirin Co Ltd Método para preparar una disolución acuosa que contiene medio de cultivo y agente quelante
WO2012145682A1 (en) * 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
MY169935A (en) 2011-04-29 2019-06-18 Biocon Biologics India Ltd "a method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof"
AU2012283667B2 (en) 2011-07-12 2015-07-09 Foodchek Systems, Inc. Culture medium, method for culturing Salmonella and E. coli and method for detecting Salmonella and E. coli
CN103748211B (zh) * 2011-07-13 2016-05-18 食品安全测试系统公司 用于李斯特菌的培养基和培养方法以及检测李斯特菌的方法
KR20170021919A (ko) 2011-10-21 2017-02-28 화이자 인코포레이티드 철을 첨가하여 세포 배양을 개선하는 방법
AU2013222188A1 (en) 2012-02-22 2014-09-11 Amgen Inc. Autologous mammalian models derived from induced pluripotent stem cells and related methods
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
ES2540753T3 (es) 2012-09-24 2015-07-13 Lonza Biologics Plc. Vectores de expresión que comprenden secuencias quiméricas de promotor y amplificador de citomegalovirus
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
ITTO20130493A1 (it) * 2013-06-14 2014-12-15 Determinants Of Metabolism Res Lab S R L Composizione per l'eliminazione di animali molesti infestanti
JP6195191B2 (ja) * 2013-08-08 2017-09-13 極東製薬工業株式会社 無タンパク質・無脂質培地馴化細胞株を用いた組換えタンパク質の製造方法
JP6190205B2 (ja) * 2013-08-08 2017-08-30 極東製薬工業株式会社 無タンパク質・無脂質培地馴化細胞株、その製造方法及び培地
US11078464B2 (en) 2013-08-30 2021-08-03 Amgen Inc. High titer recombinant AAV vector production in adherent and suspension cells
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US10634665B2 (en) 2014-09-24 2020-04-28 Triad National Security, Llc Bio-assessment device and method of making the device
JP6749898B2 (ja) 2014-10-15 2020-09-02 アムジエン・インコーポレーテツド 宿主細胞における異種由来遺伝子の発現を改善するためのプロモーター及び調節エレメント
JP6432774B2 (ja) * 2014-12-25 2018-12-05 江南化工株式会社 細胞賦活剤
CN108700568A (zh) 2016-01-06 2018-10-23 隆扎有限公司 用于改善的生产的蛋白质降解抑制剂
US10119117B2 (en) 2016-01-28 2018-11-06 Nanogen Pharmaceutical Biotechnology Co., Ltd Universal, glycosylation enhancer, completely chemically defined medium formulation
US20190055513A1 (en) * 2016-02-22 2019-02-21 Agency For Science, Technology And Research Cell culture medium
CA3017165A1 (en) 2016-03-10 2017-09-14 Lonza Ltd Customizable facility
US10689873B2 (en) 2016-03-10 2020-06-23 Lonza Ltd Customizable facility
WO2017178526A1 (en) 2016-04-14 2017-10-19 Lonza Ltd Compositions and methods for the detection of host cell proteins
TWI734775B (zh) * 2016-04-26 2021-08-01 美商美國泰福生技股份有限公司 細胞培養基
ES2938626T3 (es) 2016-05-03 2023-04-13 Lonza Ag Modulación del metabolismo de los lípidos para la producción de proteínas
AU2017277761B2 (en) 2016-06-10 2021-11-11 Lonza Ltd Method for stabilizing proteins
KR102480770B1 (ko) 2016-08-02 2022-12-22 론자 리미티드 맞춤형 시설
US20190169675A1 (en) 2016-08-12 2019-06-06 Lonza Ltd Proteomic analysis of host cell proteins
EP3512545B1 (de) 2016-09-16 2022-10-26 Leukocare AG Neuartiges verfahren zur stabilisierung eines biopharmazeutischen arzneimittelprodukts während der verarbeitung
CN106635958A (zh) * 2016-12-24 2017-05-10 严志海 一种中国仓鼠卵巢细胞培养基
CR20190397A (es) 2017-03-10 2019-09-27 Hoffmann La Roche Método para producir anticuerpos multiespecíficos
WO2018232265A1 (en) 2017-06-16 2018-12-20 Lonza Ltd Universal self-regulating mammalian cell line platform for the production of biologics
CN111868223A (zh) 2017-09-15 2020-10-30 百时美施贵宝公司 大规模生产目的多肽过程中的在线生物质电容监测
JP2021509007A (ja) 2017-12-05 2021-03-18 ロンザ リミテッドＬｏｎｚａ Ｌｉｍｉｔｅｄ トロポロンをアッセイする方法
CN116218782A (zh) 2018-02-02 2023-06-06 隆萨有限公司 细胞选择和修饰细胞代谢的方法
KR20200133240A (ko) 2018-03-16 2020-11-26 브리스톨-마이어스 스큅 컴퍼니 단백질 생산 동안의 대사 효소 활성 및 디술피드 결합 환원
US20190367858A1 (en) 2018-06-01 2019-12-05 Lonza Ltd. Midscale Model For Organic Growth and Phasing
WO2020014618A1 (en) 2018-07-13 2020-01-16 Lonza Ltd Methods for improving production of biological products by reducing the level of endogenous protein
WO2020028616A1 (en) 2018-08-02 2020-02-06 Lonza Ltd Methods for manufacturing recombinant protein comprising a disulfide bond
CN110343666B (zh) * 2019-07-10 2023-05-30 通化东宝药业股份有限公司 一种cho细胞培养的补料培养基及其制备方法和应用
US20220403398A1 (en) 2019-11-14 2022-12-22 Lonza Ltd Methods of cell selection
CN114206924A (zh) 2019-12-06 2022-03-18 瑞泽恩制药公司 抗vegf蛋白组合物及其制备方法
EP4130238A4 (de) * 2020-03-25 2024-05-15 Ajinomoto Kk Hepes-haltiges medium
JP2024503239A (ja) 2020-12-22 2024-01-25 アムジェン インコーポレイテッド 細胞培養法
WO2023045140A1 (zh) * 2021-09-26 2023-03-30 上海迈泰君奥生物技术有限公司 一种提高宿主细胞中抗体表达量的方法
CN113846051B (zh) * 2021-09-28 2023-12-01 无锡多宁生物科技有限公司 一种通用型化学成分限定cho细胞传代培养基及其应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE65933C (de) Rheinische Gesellschaft für metall Ventileinrichtung für Spirituskocher
US4205126A (en) 1978-01-01 1980-05-27 Cartaya Oscar A Serum-free cell culture media
MX197183A (es) * 1982-05-05 1994-02-28 Genentech Inc Activador de plasminogeno de tejido humano
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
FR2543158B1 (fr) 1983-03-24 1985-11-15 Inst Nat Sante Rech Med Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu
US4767704A (en) * 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4777245A (en) 1984-01-06 1988-10-11 Genelabs Incorporated Non-human primate monoclonal antibodies and methods
EP0164813B1 (de) 1984-06-14 1991-10-09 Teijin Limited Verfahren zur Züchtung tierischer oder pflanzlicher Zellen
JPS6125480A (ja) 1984-07-13 1986-02-04 Nitsusui Seiyaku Kk 細胞用の無血清合成培地
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
GB8531925D0 (en) 1985-12-31 1986-02-05 Bass Plc Propagation of yeast
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
CA1297434C (en) 1986-04-14 1992-03-17 Kenji Murakami Method of producing peptides, recombinant plasmid for use in the same and animal cells transformed with the same
US4677704A (en) * 1986-04-22 1987-07-07 Huggins Richard A Cleaning system for static charged semiconductor wafer surface
EP0248656B1 (de) 1986-06-04 1993-03-31 Director-General of the Agency of Industrial Science and Technology Zubereitung für Zellkultur und ihre Verwendung
JPS637780A (ja) 1986-06-28 1988-01-13 Nippon Zenyaku Kogyo Kk 細胞への鉄供給方法
EP0318487B1 (de) * 1986-08-04 1993-10-13 The University Of New South Wales Serumfreies gewebekulturmedium, das ein polymerzellenschutzmittel enthält
CS262822B1 (en) 1986-10-03 1989-04-14 Kovar Jan Synthetic medium for the cultivation of myelomic cells
US5045468A (en) 1986-12-12 1991-09-03 Cell Enterprises, Inc. Protein-free culture medium which promotes hybridoma growth
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP2749011B2 (ja) 1987-02-05 1998-05-13 鐘淵化学工業 株式会社 無血清培地で増殖継代可能な細胞およびその取得方法
JPS63196268A (ja) * 1987-02-10 1988-08-15 Kanegafuchi Chem Ind Co Ltd 無血清培地で継代増殖可能な形質転換細胞、その育種方法およびその細胞による蛋白質の生産方法
EP0283942B1 (de) 1987-03-24 1992-05-20 W.R. Grace & Co.-Conn. Basisnährmedium für eine Zellkultur
CA1341235C (en) 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
IL87737A (en) * 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
AU612404B2 (en) 1987-09-11 1991-07-11 Genentech Inc. Method for increasing the expression of polypeptides in recombinant cell culture
JPH02438A (ja) * 1987-10-09 1990-01-05 Collaborative Res Inc 修飾した低分子量プラスミノーゲン活性化因子およびその製造方法
FI884924A (fi) 1987-10-28 1989-04-29 Oncogen Humanimmuglobulin som producerats med hybrid-dna-teknik.
DE3801236A1 (de) * 1988-01-18 1989-07-27 Boehringer Mannheim Gmbh Pentosansulfat-medium
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
WO1989007452A1 (en) * 1988-02-12 1989-08-24 Medical Research Council Improvements in or relating to antibodies
AU4312489A (en) 1988-09-23 1990-04-18 Cetus Corporation Lipid microemulsions for culture media
CA1341552C (en) 1988-09-23 2007-10-02 Kenneth Alonso Method of producing human-human hybridomas, the production of monoclonal and polyclonal antibodies therefrom, and therapeutic use thereof
JPH0322972A (ja) * 1989-01-12 1991-01-31 Ajinomoto Co Inc 無血清培地
IL93463A0 (en) * 1989-02-27 1990-11-29 Lilly Co Eli Improved tissue culture method
US5135866A (en) 1989-03-03 1992-08-04 W. R. Grace & Co.-Conn. Very low protein nutrient medium for cell culture
CA2001550A1 (en) * 1989-03-03 1990-09-03 Aaron H. Heifetz Very low protein nutrient medium for cell culture
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
EP0404003A3 (de) 1989-06-19 1991-10-16 Xoma Corporation Chimäre Maus-Mensch-KM10-Antikörper, spezifisch für ein menschliches Tumorzellen-Antigen
EP0493433B1 (de) 1989-09-19 1996-01-10 Centocor, Inc. Verfahren zur verbesserten herstellung von menschlichen antikörpern sowie hierzu benutzte zellen
WO1991010722A2 (en) 1989-12-27 1991-07-25 Centocor, Inc. Chimeric immunoglobulin for cd4 receptors
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
DE4115722A1 (de) 1991-05-14 1992-11-19 Boehringer Mannheim Gmbh Serumfreies medium zur kultivierung von saeugerzellen
EP0523949B1 (de) 1991-07-15 2003-06-25 The Wellcome Foundation Limited Herstellung von Antikörpern
CZ289472B6 (cs) 1991-07-25 2002-01-16 Idec Pharmaceuticals Corporation Chimérická protilátka, nukleová kyselina, která ji kóduje, způsob její produkce a farmaceutická kompozice, která ji obsahuje
AU671807B2 (en) 1991-10-15 1996-09-12 Btg International Limited CDw52 - specific antibody for treatment of T-cell mediated inflammation of the joints
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
KR20010069066A (ko) 2000-01-12 2001-07-23 이종원 저산소 농도하에서 생존이 가능하도록 하는 동물세포의배양방법
ATE419005T1 (de) 2001-12-11 2009-01-15 Merck & Co Inc Staphylococcus aureus exopolysaccharid und verfahren

Also Published As

Publication number Publication date
EP1849862A2 (de) 2007-10-31
DK0481791T3 (da) 2003-12-08
US5633162A (en) 1997-05-27
JPH0670757A (ja) 1994-03-15
EP1221476A2 (de) 2002-07-10
ZA918249B (en) 1993-04-16
CA2053586C (en) 2003-07-29
NZ240248A (en) 1994-11-25
ES2298301T3 (es) 2008-05-16
DE69133303D1 (de) 2003-10-02
AU8591591A (en) 1992-05-07
GB9022545D0 (en) 1990-11-28
CA2053586A1 (en) 1992-04-18
DE69133589T2 (de) 2009-01-08
EP0481791B1 (de) 2003-08-27
EP0481791A2 (de) 1992-04-22
EP1221476A3 (de) 2003-09-17
ATE248217T1 (de) 2003-09-15
JP2625302B2 (ja) 1997-07-02
ES2204885T3 (es) 2004-05-01
USRE39792E1 (en) 2007-08-21
DK1221476T3 (da) 2008-05-13
US5316938A (en) 1994-05-31
DE69133589D1 (de) 2008-02-14
EP0481791A3 (en) 1992-07-08
DE69133303T2 (de) 2004-06-24
EP1849862A3 (de) 2008-02-13
USRE41974E1 (en) 2010-11-30
EP1221476B1 (de) 2008-01-02
IE913559A1 (en) 1992-04-22
AU645615B2 (en) 1994-01-20

Similar Documents

Publication Publication Date Title
ATE382680T1 (de) Nährmedium für cho-zellen und daran angepasste zellen
Azam et al. Cycling of organic matter by bacterioplankton in pelagic marine ecosystems: microenvironmental considerations
PT610474E (pt) Cultura de celulas animais
IT8820695A0 (it) Metodo per il controllo dell'esatto posizionamento degli oggetti da smistare in un impianto di smistamento automatico.
HK1000074A1 (en) Method to preselect the sex of offspring
MX166885B (es) Metodos de purificacion y reactivacion de proteinas heterologas precipitadas
IL107564A (en) Nucleic acid encoding PstS variants method for production and method for controlling polypeptide production in bacteria transformed by said nucleic acid
SE8500621L (sv) Forbettrad proteinframstellning med anvendning av hypertoniska medier
Srivastava et al. Enzymatic action of lipoglycoprotein preparations from sperm-acrosomes on rabbit ova
GB2196636B (en) Production of proteins by cell culture
ES2194273T3 (es) Regulacion de la produccion de inmunoglobulinas por la interleucina-9.
CA2286323A1 (en) Cell culture media for enhanced protein production
ATE168717T1 (de) Zellkulturverfahren und medium für das wachstum adhärenter tierzellen
DE69011622D1 (de) Verwendung von geschützten Aminosäuren in Futtermitteln für Schafe.
EP0348947A3 (en) Prevention or elimination of mycoplasma contamination of animal or plant cell culture
DE3774086D1 (de) Laktoferrin enthaltendes inkubationsmedium fuer festphasen-immunometrische verfahren und seine verwendung.
Marcus et al. Iron requirement for isolated rat liver mitochondrial protein synthesis
ZA909562B (en) Generation of transgenic vertebrates by employing transformed sperm cells via artificial insemination and transgenic vertebrates generated thereby
IT1244747B (it) Metodo per la fermentazione contemporanea di un amminoacido basico e di un amminoacido acido
GB9828624D0 (en) Production of proteins
GB1208225A (en) Process for purifying l-asparaginase
Prather et al. Activation of porcine oocytes matured in vitro
Imada et al. Identification of 200,000-dalton human cell surface protein encoded by gene mapped to long arm of chromosome 11
UA8276A (uk) Спосіб виготовлення гама-інтерферонів та пристрій для його здійснення
Williams et al. Development of bovine embryos in media containing plasminogen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1221476

Country of ref document: EP

EELA Cancelled due to lapse of time